Histologie Analysis
Ali specimens were submitted to standard histologie examination, to confirm diagnosis of condylomata acuminata (S.Y., H.B.). The most representative lesions were used for HPV genotyping.
HPV Genotyping
DNA was purified from fresh biopsy samples or paraffin-embedded material using the Magna Pure DNA isolation kit (N°3003990, Roche, Rotkreuz, Switzerland) on the Magna LC robot (Roche). Negative controls accompanied each set of DNA extractions assess contamination. Typing was performed at the Institute of Microbiology as part of its routine diagnostic testing using accredited procedures (ENI 7025) that will be published elsewhere (Estrade et al., In press). Briefly, HPV DNA was detected by polymerase chain reaction (PCR) and genotyped by reverse line blot hybridization (RLBH). PCR was performed with 5 µL DNA in triplicate 50 µL reactions using the PGMY primers, according to Gravitt et al., 24 with slight modifications. The PGMYI J primers and one of the HLA primers were biotinylated to detect the amplicon in the genotyping by RLBH. PGMY primers were used at 80 nM, HLA at 40 nM in 1 X PCR buffer II (Applied Biosystems, Rotkreuz. Switzerland), 0.2 mmol/L dNTPs, 1.5 mmol/L MgCl 2 , and l .25 units of AmpliTaq Gold (Applied Biosystems). HLA-DQA primers 2 5 were used as an internai standard to assess the quality of the DNA and absence of PCR inhibitors. Positive controls (HPV16 DNA from Caski cells) and negative controls (PCRgrade water) were systematically analyzed to ensure appropriate sensitivity of the reaction (at least 100 copies ofHPV DNA) and absence of contamination, respectively. Following PCR. 5 µL of each reaction were analyzed by gel electrophoresis and staining with ethidium bromide. Samples were considered informative if the HLA or the HPV DNA fragment could be detected. RLBH was performed on positive samples by RLBH with a miniblotter (MN 45, Immunetics, Boston) essentially as described by Kaufhold et al. 26 27 To identify types not represented in the panel of probes, sequencing was performed on PCR-positive/hybridization-negative samples with sequencers from Applied Biosystems using the Big Dye Terminator chemistry (BDT v.1.1, Applied Biosystems) and PGMYl 1 primers.
Sectioning of the paraffin block was donc with singleuse disposable blades to eliminate the risk of intersample contamination. Standard procedures to avoid PCR contaminaAnal tion were strictly followed: work was done in separate laboratories (pre-and post-PCR analysis).
Definition
Recurrence was defined as the advent of new lesion(s) within 12 months after curative surgery. This delay was chosen arbitrarily, as the literature is vague about this definition. Furthermore, in patients without visible warts after treatment, there is no way to verify whether the viral infection has becn completely cleared or whether it is present and latent, at the site of previous resection or on adjacent mucosa. 2 As clinical warts depend upon the presence of HPV, it is difficult to determine whether ACA will recur in this context.
Follow-Up
Two groups of patients were defined: those without and those with recurrent disease. New lesions were surgically excised and diagnosis of ACA was confirmed by histology. Recurrencc rates and tiJne to recurrence after surgery were calculated.
Statistical Analyses
To compare patients' distribution, Pearson homogeneity test (x 2 ) was used. When theoretical numbers were <5, the Monte-Carlo simulation test was used with 2000 simulations. 28 Wilcoxon test was performed for age. Statistical analysis was performed with R software (version 2.2.1). 29 To fulfill basic statistical rules for analysis and thus to obtain independent data, only the first lesion was considered. Significance was assumed to occur at P <0.05.
RESULTS
One hundred forty consecutive patients were included in this study. Median age was 35.3 years (SD = 11.7). Of the 123 (88%) males, 40 (32%) declared themselves to be heterosexuals, 73 (60%) homosexuals, and 10 (8%) bisexuals. Of the 17 (12%) females, 16 (94%) were heterosexual and 1 (6%) was bisexual.
Recurrence occurred in 35 (25.0%, 1 female and 34 males) patients, 21 to 357 days after curative surgery (median 120 days). Median age of the nonrecurrent and recurrent group was 36.4 (SD = 12.4) and 31.9 (SD 1 = 8.7), respectively. Age and gender did not represent a risk factor for recurrence (P >0.05).
Median follow-up was 32 months (SD = 35.4); this included both the clinical follow-up and the information provided in the retumed questionnaires (of the questionnaires sent out, 71 % were retumed).
HPV Types
Initially, 144 patients had histologically confirmed primary ACA; 4 of tbem were excluded because conclusive typing of HPV was not possible (no DNA could be amplified One hundred five among 140 (75%) patients were infected by a single HPV, and 24 of them recurred. Twenty-eight among 140 (20%) patients presented a mixed infection, and 10 of them recurred. When compared, neither none, single nor mixed infections were associated with statistically higher recurrence rates P >0.05 (Table 2) .
Among the 10 patients with mixed infections which recurred, 9 contained HPV 11, and 1 did not. There was a significant correlation between mixed infection associating HPV 11 and recurrence compared to mixed infection without HPY 11 (P <0.05).
HIV Status
Thirty-three (24%) patients were HIV-positive, 97 (69%) HIV-negative, whereas in 10 (7%) patients HIV status 
DISCUSSION
Possible correlation between HPV type and recurrence of ACA has been little studied and remaîns debatable. Nevertheless, ACA are very frequent and, apart from HIV seroposîtivity, no other specific risk factor for recurrent ACA has been described in the literature.
For the purposes of this article, to obtain independent data and to fulfil basic statistical rules for analysis, only the first lesion was considered. According to the definition of recurrence (mentioned in Definition under Materials and Methods), only recurrences within 1 year were considered. Interestingly, the earliest clinical wart described after the period of 12 months was at 20 months. This "8-month-gap" suggests that the definition currently used can be considered as adequate. Unfortunately, no other data were available to supp01t this statement. However, it is noted that Nathan et al.3° also considered their patients as cured after a 12-months disease-free period after Jaser ablative therapy for HPV-associated anal canal disease.
Among the 140 patients, 7 (5%) had no HPV identified. These patients should arguably be excluded. However, 1 of these 7 patients presented with recurrence. Ali 7 have therefore been included in the study, considering that this situation could paradoxically represent a risk factor for recurrence. However, as expected, statistical analysis showed that absence of viral DNA was indeed not a risk factor. Because of this singular patient, ail 7 were nevertheless included in the analysis, even though they made the case for HPV 11 weaker.
In the current study, neither age nor gender represented a risk factor for recurrence. Nevertheless, they both verge on statistical significance (P = 0.080 and 0.064, respectively).
Median age of the recurrence group was only 4.5 years younger than the nonrecurrence group. Thus, the population cannot be divided in 2 specific separate groups as the ages are too close. This is also supported by Nathan et al. 30 who showed that outcome of laser treated HPV-associated anal canal diseases were not affected by age.
The distribution of the 34/l recurrent males/female makes the genders difficult to compare and the P value of 0.080 difficult to analyze. HPV 6 and 11 were the most frequently encountered viruses. This is consistent with the results published by Dupin 31 who showed that mucosal HPV 6 and 11 are the types most frequently found in patients with genital warts or condylomata acuminata. This deduction is also supported by Kreuter et al. 32 The whole of their cohort of patients excised by surgery for intraanal condylomata carried HPV 6 or 11.
HPV 11 was associated with statistically higher recurrence rates, when present alone and also in mixed infections. Venturoli et al. 33 Che et al. 34 also studied HPV and recurrence of condylomata but they did not mention exactly where the lesions recurred: whether vagina, penis, or anus. Their work concentrated on HPV DNA loads rather than HPV typing. They found HPV Type 6 or 11 in 98.4% of cases (recurrent or not) but used a Fluorescence Quantitative PCR Diagnostic Kit, which does not differentiate HPV 6 from 11. Kreuter et aJ.3 2 studied the HPV DNA load by HIV-infected men treated with 5% imiquimod suppositories after surgical ablation, using electrocautery, of intraanal condylomata acuminata. They showed that the suppositories Jed to a sharp decrease in HPV DNA Joad and concluded that larger clinicaJ trials are needed to find out whether relapse rates with the use of imiquimod after surgery are significantly lower than with surgery aJone. Only 7 patients were incJuded in their study and they also did not anaJyze the correJation between HPV type and recurrence. So, neither of these 2 studies can readiJy be compared with our results in terms of HPV typing and recurrence.
The present series shows that HIV seropositivity does not apparently influence ACA recurrence as suggested by Stevens et al. 35 EpidemioJogic studies have shown that HIV seropositivity and other conditions are risk factors for HPV infection among women. 2 ·3 Nothing was said about risk factors for recurrence. Other studies need to be petformed to determine if HIV seropositivity really acts as an independent risk factor on the prevalence of HPV infection and recurrent disease. The low recurrence rate demonstrated among HIV-positive patients suggests that our surgical technique was of importance: en bloc resection with a free margin of normal tissue ensured clearance, and diathermy, systematically used to obtain hemostasis, prevented any residuaJ virus frorn being left on the resection site. CD4 count of the patients was not known at the time of surgical treatment, which makes their reaJ immune competence difficult to detetmine. However, SancJemente et al. 36 showed in a series of 37 patients that the efficacy of 5% imiquimod in HIVpositive male patients suffering from anogenital warts or anal intraepithelial neoplasia was not inftuenced by patients' CD4 count, HIV viral load, or HPV viral load, meaning that recurrence was not inftuenced by HIV status. This is consistent with our series.
A severity scoring system for condylomata presented at the American Society of Colon and Rectal Surgeons 2004
Meeting suggested a scale of 0 to 5 applied to 3 areas: the intraanaJ, perianal, and extraanal regions. 35 The 3 scores were added to create the condyloma scoring system (maximum 15) as a predictor of recurrence. The Jack of information in our retrospectively analyzed cohort unfortunately did not allow use of this algorithm.
We found HPV 6 and 11 to be the most frequently identified viruses. Compared with ail others, HPV 11 seemed to change the course of the disease with statistical significance (P == 0.004) and it confers an increased risk of recurrent ACA.
Routine clinical HPV typing remains, however, questionable. In the absence of any proven benefit, the additionaJ cost of investigation and treatment is difficult to justify when based soJely on analysis of a retrospective cohort of 140 patients extending over a period of 15 years. At this point, we cannot yet recommend systematic HPV typing, its reJevance not having been conclusively demonstrated. Prospective data based on recurrence, costs, and clinical implication are needed. NeverAnal theless, follow-up is required to identify recurrence and to treat it carly, cspecially if HPV 11 has been indcntified.
